Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more
Adalta Ltd (1AD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 3.267x
Based on the latest financial reports, Adalta Ltd (1AD) has a cash flow conversion efficiency ratio of 3.267x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.95 Million) by net assets (AU$-598.24K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Adalta Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Adalta Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Adalta Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adalta Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IA Invest Advice Capital Glob
CO:IAIACG
|
N/A |
|
COSUMAR
BC:COSUMAR
|
N/A |
|
CARDETY (CUX1.SG)
STU:CUX1
|
0.018x |
|
STANDARD CHARTERED (STD.SG)
STU:STD
|
-0.009x |
|
BYC Co. Pfd. Ltd. Series 1
KQ:001465
|
N/A |
|
GP EUROTUNNEL RGPT
MU:TNU3
|
N/A |
|
GPGI, Inc.
NYSE:GPGI
|
-0.078x |
|
LAGARDERE SCA N (LAG.SG)
STU:LAG
|
0.035x |
Annual Cash Flow Conversion Efficiency for Adalta Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Adalta Ltd from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-598.24K | AU$-2.94 Million | 4.909x | +289.49% |
| 2024-06-30 | AU$2.03 Million | AU$-5.26 Million | -2.590x | +3.59% |
| 2023-06-30 | AU$1.91 Million | AU$-5.13 Million | -2.687x | -253.48% |
| 2022-06-30 | AU$5.38 Million | AU$-4.09 Million | -0.760x | -1.52% |
| 2021-06-30 | AU$6.39 Million | AU$-4.78 Million | -0.749x | +52.93% |
| 2020-06-30 | AU$3.70 Million | AU$-5.89 Million | -1.591x | -104.89% |
| 2019-06-30 | AU$7.49 Million | AU$-5.82 Million | -0.776x | +19.51% |
| 2018-06-30 | AU$4.07 Million | AU$-3.93 Million | -0.965x | -100.48% |
| 2017-06-30 | AU$7.75 Million | AU$-3.73 Million | -0.481x | -334.96% |
| 2016-06-30 | AU$10.62 Million | AU$-1.17 Million | -0.111x | +94.35% |
| 2015-06-30 | AU$705.89K | AU$-1.38 Million | -1.958x | +73.76% |
| 2014-06-30 | AU$172.82K | AU$-1.29 Million | -7.465x | -219.41% |
| 2013-06-30 | AU$283.92K | AU$-663.54K | -2.337x | -- |